Clinical trials: Relapsed/Refractory Myeloma
Relapsed/Refractory Multiple Myeloma (RRMM)
A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.
- Trial name
- NCT07667868
- Testing
- BP2202
- Volunteers
- 18 people
- Sponsor
- BrightPath Biotherapeutics Co., Ltd.